I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Ovarian cancer is the most lethal gynecologic malignancy at present. Despite the recent new diagnostic possibilities and medical advances, the 5-year survival rate of patients with advanced ovarian cancer is only 25--35%.\[[@ref1]\] Prognosis is usually very poor due to the late diagnosis, more than 70% of patients diagnosed with this cancer have reached late-stage (stage III-IV) when cancer has already spread beyond the ovaries.\[[@ref2]\] One reason for this high mortality rate is the lack of an effective early detection method for ovarian cancer. Indeed, the 5-year survival rate at early-stage (stage I-II) can reach 90%.\[[@ref3]\] Therefore, there is immediate need of reliable diagnostic biomarkers and novel therapeutic tools that can realize the early diagnosis of ovarian cancer. Among this, the recently discovered microRNAs (miRNAs) have been learned a lot. A total of 2578 human miRNAs have been found until now (Sanger miRBase database, version 20.0). Moreover, studies have found that miRNAs play a key role in various biological processes of ovarian cancer, such as development, proliferation, differentiation, apoptosis, and metastasis. These phenomena appear in early-stage, suggesting miRNA can be used as a new biomarker for early diagnosis of ovarian cancer.\[[@ref4]\] This review summarizes the current clinical diagnosis method and diagnostic biomarkers of ovarian cancer, and the early detection methods of ovarian cancer miRNAs are explored.
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Conventional diagnostic methods for ovarian cancer include the history of disease, physical examination, symptom index diagnosis and imaging diagnosis, etc. History of disease and physical examination can only understand the general condition of patients while symptom index diagnosis is an only preliminary clinical evaluation.\[[@ref5]\] Imaging diagnostic methods mainly include ultrasonic, computed tomography (CT) scan, magnetic resonance imaging (MRI), and positron emission tomography-CT (PET-CT), etc.\[[@ref6]\]

Ultrasound diagnosis is widely used due to the low price and low radiation hazard, which is an important diagnostic method for ovarian cancer, but it has limited specificity and sensitivity.\[[@ref7]\] Therefore, ultrasound diagnosis should not be used alone as the screening method for ovarian cancer but should be combined with other test results to analyze comprehensively and diagnose early-stage ovarian cancer. CT imaging is better than ultrasound in display and preoperative staging of tumors. Its diagnostic sensitivity can reach 73.2%.\[[@ref8]\] However, CT diagnosis has several defects such as low specificity and ionizing radiation. Compared with CT, MRI has the function of the multi-dimensional imaging. It provides better soft tissue contrast in the pelvic examination, and the sensitivity is obviously improved than CT (MRI for 90%, CT for 66%).\[[@ref9]\] However, MRI is expensive, which is not suitable for ovarian cancer screening in the general population. Based on the tracking of radioactive tracer, PET-CT can provide information of cell anabolic metabolism rate, identify target cells in a specific organization and reflect the metabolic changes of tumor cells. Therefore, compared with CT or MRI, PET-CT has higher sensitivity in the diagnosis of ovarian cancer recurrence. However, its diagnostic accuracy is not ideal for early-stage, small, and low-grade malignant tumors. There may easily appear false positives and false negatives.\[[@ref10]\]

Imaging diagnosis method is a normal method for clinical tumor diagnosis. But due to the various defects of the image device, it is usually to combine several kinds of technologies for diagnosis. Moreover because of the low sensitivity and specificity, the methods are often used in the diagnosis of high-risk groups, rather than early detection. Therefore, it is urgently needed to develop new methods for early diagnosis of ovarian cancer.
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In addition to the formation of ovarian cancer and the limitations of conventional diagnostic methods, the selection of biomarkers is also a big influencing factor on the difficulty of early diagnosis of ovarian cancer. A biomarker is a kind of chemical substance reflecting the existence of tumor. Occurrence and development of tumor can be understood through the existence and changes of biomarkers, thus assisting diagnosis, classification and prognosis judgment on tumor and guidance on tumor treatment.\[[@ref11]\] The ideal biomarker needs good specificity, high sensitivity and should be closely related to tumor progression.

Ovarian cancer-related biomarkers at present are mainly carbohydrate antigen, lysophosphatide acid, human epididymis protein 4, nectin-4 and tyrosine kinase receptor, etc.\[[@ref12]\] Until now, diagnostic index that is used in clinical for diagnosis, recurrence and prognosis of patients with ovarian cancer is still CA-125 only. However, CA-125 has many limitations in the diagnosis of ovarian cancer. First, its diagnostic sensitivity is low. The preoperative diagnostic sensitivity for patients with ovarian cancer of stage I and II is lower than 60%,\[[@ref13]\] so it cannot realize the early detection on small and curable cancer. In addition, its diagnostic specificity is poor. CA-125 is increased to different degrees in lung cancer, liver cancer, pancreatic cancer, cervical cancer, colorectal cancer, and other malignant tumors,\[[@ref14]\] so there are some false positives.\[[@ref15][@ref16]\]

For these reasons, European Group on Tumor Marker and National Academy of Clinical Biochemistry do not claim to use CA-125 as biomarkers in early diagnosis of ovarian cancer.\[[@ref17][@ref18]\] Therefore, a lot of researchers are devoted to seeking a new diagnostic biomarker with strong specificity.
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miRNA was discovered by Victor Ambros *et al*.\[[@ref19]\] in 1993 in their study on lin-14 gene regulating development of nematodes. Mature miRNA is a kind of endogenous, noncoding, single-stranded small RNA, which is composed of about 20--22 nucleotides.\[[@ref20]\] In this review, we summarized the biogenesis and function of miRNA \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref21]\] MiRNA is involved in many physiological processes and is expressed abnormally in a variety of pathological conditions. These abnormal expressions of miRNA are closely related to the occurrence and development, and diagnosis and prognosis of the human disease, and form the specific characteristics of diseases spectrum. These characteristics contribute in the high specificity of miRNA to target gene. Compared to protein markers, miRNA changes before the protein and along with the progress of tumor.\[[@ref22]\] In addition, miRNA is small and can effectively avoid degradation in an endogenous and exogenous fluid, so miRNA is more stable than DNA and messenger RNA (mRNA).

![Overview of microRNA biogenesis and function. At first, primary microRNA transcribed by genome is processed in the nuclei by Drosha enzyme to become precursor microRNA of stem-loop structure (70--100 nucleotides). Then precursor microRNA is transferred from nuclei to cytoplasm via RanGTP/exprotin-5 transport mechanism (RanGTP concentration is higher in nuclei, and exprotin-5 can promote precursor microRNA to release from Drosha complex and bring it to the outside by combining with it; while RanGTP is lower in cytoplasm and precursor microRNA is released by exprotin-5). At last, precursor microRNA is digested by another double-stranded RNA-specific ribonuclease (Dicer) to finally obtain the mature microRNA consisting of 20--22 nucleotides. MicroRNAs combined with RNA-induced silencing complex and bind to 3'-untranslated region of target messenger RNA. These mature microRNAs may set up complete or incomplete base pairing with messenger RNA to degrade target messenger RNA or lead to inhibitions on translation and further regulate the gene expressions after gene transcription.](CMJ-128-3363-g001){#F1}

Different kinds of tumors have different miRNA expression spectrum. A lot of studies over the comparison between normal ovary tissue and ovarian cancer tissues in miRNA expression showed that there were significant changes of miRNA in ovarian cancer tissue. Iorio *et al*.\[[@ref23]\] compared 29 tissue miRNAs between epithelial ovarian cancer patients and healthy controls. The results showed that only 4 miRNAs (miR-141, miR-200a, miR-200b, and miR-200c) were up-regulated, and 25 miRNAs were down-regulated, where miR-125b-1, miR-140, miR-145, and miR-199a had the highest multiples of down-regulation. They suggested that the aberrant expression of miRNAs could exert on the pathogenesis and the development of different histotypes of ovarian carcinoma. Further study found that stage I epithelial ovarian cancer histotypes have their own characteristic miRNA expression and specific regulatory circuits.\[[@ref24]\] The result showed that miR-30a-5p and miR-30a-3p were increased in clear cell histotype, indicated that miR-30a-5p and miR-30a-3p could be a stage-independent clear cell marker; whereas miR-192 and miR-194 were significantly highly expressed in mucinous histotype, suggested that miR-192 and miR-194 were key markers of mucinous subtypes. Recently, multiple studies prove that miRNA expression signature can be identified as potential prognostic indicators, which are summarized in [Table 1](#T1){ref-type="table"}.\[[@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32]\]

###### 

Potential prognostic miRNAs for ovarian cancer

  Tumor histology (*n*)   miRNA                         Endpoint                                      Prognosis   Reference
  ----------------------- ----------------------------- --------------------------------------------- ----------- --------------------
  EOC (48), PPC (7)       miR-200a, miR-200b, miR-429   Overall survival                              Good        \[[@ref25]\], 2009
  SAC (185)               miR-410, miR-645              Overall survival                              Good        \[[@ref26]\], 2011
  EOC (98)                miR-100                       Overall survival                              Good        \[[@ref27]\], 2012
  EOC (176)               miR-187                       Overall survival, recurrence-free survival    Good        \[[@ref28]\], 2012
  EOC (100)               miR-150                       Overall survival, progression-free survival   Good        \[[@ref29]\], 2014
  EOC (36)                miR-335                       Overall survival, recurrence-free survival    Good        \[[@ref30]\], 2014
  EOC (146)               miR-196a                      Overall survival, recurrence-free survival    Poor        \[[@ref31]\], 2015
  EOC (211)               let-7a                        Overall survival                              Good        \[[@ref32]\], 2015

SAC: Serous adenocarcinoma; EAC: Endometrioid adenocarcinoma; miRNAs: MicroRNAs; PPC: Primary peritoneal carcinomas.

Tissue miRNA cannot be used for early detection because tissue samples at or post diagnosis are required. Studies have shown that serum/plasma miRNA has obvious advantages as a tumor marker:\[[@ref33]\] First, miRNA is involved in all stages of tumor including occurrence, development, and metastasis, with good specificity; next, serum/plasma miRNA, both stable and insensitive to ribonuclease, temperature, and pH, can be preserved for a long time while can be frozen and unfrozen repeatedly; finally, it is simple to detect serum/plasma miRNA, with low cost. These features make the serum/plasma miRNA become a promising potential noninvasive diagnostic marker. Resnick *et al*.\[[@ref34]\] detected serum miRNA of 28 patients with serous ovarian cancer and 15 normal controls. The result showed that serum miR-92, miR-93, miR-21, miR-29b, and miR-126 in patients with ovarian cancer were significantly highly expressed, and miR-99b, miR-127, and miR-155 were lower expressed. It is worth mentioning that in these patients, miR-92, miR-93, and miR-21 have appeared before the increase of CA-125, suggesting these three kinds of miRNA can be used as the early diagnosis marker for serous ovarian cancer. Häusler *et al*.\[[@ref35]\] using a miRNA microarray to analyze the whole blood-derived miRNA expression in 24 cases of serous ovarian cancer patients and 15 cases of healthy controls (HCs). The authors reported that miR-30c-1-3p was highly expressed and miR-181a-3p, miR-342-3p, and miR-450-5p were lowly expressed in serous ovarian cancer patients. In addition, these miRNAs had good specificity (88.1%) and sensitivity (86.7%) when compared with control group. Chung *et al*.\[[@ref36]\] compared 2222 kinds of miRNAs between 18 ovarian cancer patients and 12 HCs. Four miRNAs (miR-132, miR-26a, let-7b, miR-145, and miR-143) were significantly under-expressed in the serum of serous ovarian cancer patients compared to controls. The results suggested that these miRNAs could be used as novel biomarkers of serous ovarian cancer. Zheng *et al*.\[[@ref37]\] found that plasma miR-205 was up-regulated and plasma let-7f was down-regulated in ovarian cancer cases than in controls, and combined these miRNAs could be useful biomarkers for ovarian cancer detection, especially in patients with stage I disease (specificity was 77.8% and sensitivity was 90.0%), they also found that let-7f may be predictive of ovarian cancer prognosis. Hong *et al*.\[[@ref38]\] showed that serum miR-221 may have a role as a noninvasive diagnostic marker in epithelial ovarian cancer. Furthermore, the over-expression of miR-221 was an independent unfavorable prognostic factor in epithelial ovarian cancer. Zuberi *et al*.\[[@ref39]\] reported that the expression of miR-200a, miR-200b, and miR-200c were significantly up-regulated in the serum of epithelial ovarian cancer patients compared with normal controls. Interestingly, the results also showed that miR-200a over-expression was found be associated with tumor, histology, and stage; miR-200c over-expression was found be associated with lymph node metastasis. They suggested that serum miR-200a, miR-200b, and miR-200c were recognized as reliable markers to predict the prognosis and survival in epithelial ovarian cancer patients. Liang *et al*.\[[@ref40]\] showed that serum miR-145 could discriminate patients with ovarian cancer from HCs, suggested that it could potentially serve as an outstanding biomarker for ovarian cancer. Gao *et al*.\[[@ref41]\] reported that serum miR-200c and miR-141 were significantly increased in ovarian cancer patients compared with controls. In particular, the group with high miR-200c level achieved significantly a higher 2-year survival rate, while low miR-141 group showed a significantly higher survival rate. The results showed that miR-200c and miR-141 might be predictive biomarkers for ovarian cancer prognosis. All these studies prove the thought that the detection of ovarian cancer-associated miRNAs from the peripheral blood can be an important method for early diagnosis of this disease. These are summarized in [Table 2](#T2){ref-type="table"}.\[[@ref34][@ref35][@ref36][@ref37][@ref38][@ref39][@ref40][@ref41]\]

###### 

Potential diagnostic miRNAs for ovarian cancer

  Tumor histology             Sample        Elevated miRNA                             Decreased miRNA                       Control   References
  --------------------------- ------------- ------------------------------------------ ------------------------------------- --------- --------------------
  SAC                         Serum         miR-21, miR-92, miR-93, miR-126, miR-29b   miR-155, miR-127, miR-99b             HC        \[[@ref34]\], 2009
  SAC                         Whole blood   miR-30c-1-3p                               miR-181a-3p, miR-342-3p, miR-450-5p   HC        \[[@ref35]\], 2010
  SAC                         Serum                                                    miR-132, miR-26a, let-7b, miR-145     HC        \[[@ref36]\], 2013
  SAC, MAC                    Plasma        miR-205                                    let-7f                                HC        \[[@ref37]\], 2013
  SAC, other                  Serum         miR-221                                                                          HC        \[[@ref38]\], 2013
  MAC                         Serum         miR-200a, miR-200b, miR-200c                                                     HC        \[[@ref39]\], 2015
  SAC, MAC, CAC, EAC, mixed   Serum                                                    miR-145                               HC        \[[@ref40]\], 2015
  SAC, MAC, CAC, EAC, other   Serum         miR-200c, miR-141                                                                HC        \[[@ref41]\], 2015

SAC: Serous adenocarcinoma; CAC: Clear cell adenocarcinoma; EAC: Endometrioid adenocarcinoma; MAC: Mucinous adenocarcinoma; HC: Healthy control; miRNAs: MicroRNAs.

miRNA plays a biological role via combining with 3′-untranslated region (3′UTR) of target mRNA, and then triggering either mRNA degradation or translational repression. Therefore, it can function as master coordinators, efficiently regulating and coordinating multiple cellular pathways and processes. Increasing evidence has led to the view that the expression of miRNAs is remarkably deregulated in ovarian cancer, suggesting that miRNAs may play important roles in multiple biological processes such as angiogenesis,\[[@ref42]\] adhesion,\[[@ref43]\] migration,\[[@ref43][@ref44]\] cell proliferation,\[[@ref45]\] etc., and intervention on miRNA expression of known target genes and potential target genes can be novel treatment strategies for ovarian cancer therapy, as summarized in [Table 3](#T3){ref-type="table"}.\[[@ref42][@ref43][@ref44][@ref45][@ref46][@ref47][@ref48][@ref49]\]

###### 

Potential therapeutic miRNAs for ovarian cancer

  miRNA                Target gene      Cell line                                                                                                                 Cellular function           References
  -------------------- ---------------- ------------------------------------------------------------------------------------------------------------------------- --------------------------- --------------------
  miR-484              VEGFB, VEGFR2    MDAH-2774 (EOC), SKOV-3 (EOC)                                                                                             Angiogenesis                \[[@ref42]\], 2013
  miR-92a              ITGA5            HeyA-8 (SAC), SKOV3ip1 (SAC), OVISE (CAC), RMG-1 (CAC), A2780 (SAC), CaOV3 (SAC)                                          Adhesion, migration         \[[@ref43]\], 2013
  miR-200a, miR-200b   IL-8, CXCL1      OVCAR8-ip1 (SAC), ES2 (SAC), HeyA-8 (SAC), OVCAR5 (SAC), A2780 (SAC), A2774 (SAC), IGROV1-ap1 (SAC), SKOV3ip1 (SAC)       Angiogenesis, migration     \[[@ref44]\], 2013
  miR-506              CDK4, CDK6       SKOV3 (EOC), OVCA432 (EOC), OVCA433 (EOC), HeyA-8 (SAC)                                                                   Proliferation, senescence   \[[@ref45]\], 2014
  miR-199b-5p          JAG1             A2780 (EOC), SKOV3 (EOC), ES 2 (EOC)                                                                                      Chemoresistance             \[[@ref46]\], 2014
  miR-939              APC2             SKOV-3 (EOC), CAOV-3 (EOC), HO-8910 (EOC), ES-2 (EOC), A2780/DDP (EOC)                                                    Proliferation               \[[@ref47]\], 2015
  miR-661              INPP5J           COV362 (EOC), SKOV3 (EOC), A2780 (EOC), OVCAR4 (EOC), EFO-21 (EOC), EFO-27 (EOC), TOV-21G (EOC), OV90 (EOC), OV56 (EOC)   Proliferation               \[[@ref48]\], 2015
  miR-205              VEGFR1, VEGFR2   HO-8910PM (SAC), SKOV-3ip (SAC)                                                                                           Invasion                    \[[@ref49]\], 2015

EOC: Epithelial ovarian carcinomas; SAC: Serous adenocarcinoma; CAC: Clear cell adenocarcinoma; miRNAs: MicroRNAs.
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How to realize the early diagnosis of ovarian cancer and excellent detection method are the important factors to improve the detection sensitivity and specificity. The sequence of mature miRNA is generally very short, and there is interference of cross-hybridization of sequences between homologous miRNAs, so the new challenge is put forward in detection sensitivity and specificity, etc. A large number of miRNA detection methods are emerging in recent years. Common miRNA detection methods mainly include northern blotting, microarray, and reverse transcription-polymerase chain reaction (RT-PCR). Northern blotting can identify the expression of the corresponding gene by detecting the expression of RNA, and it can realize a semi-quantitative analysis of miRNA by combing with RNA marker. Lu *et al*.\[[@ref50]\] applied northern blotting to explore the construction of eukaryotic expression vector miR-101 and its expression in human placental villi carcinoma, and the results showed miR-101 can significantly inhibit translation of endogenous EZH2, thus regulating tumor occurrence and infiltration. Northern blotting does not need to preamplify miRNA samples, but its sensitive is low, and the requirement of the sample is large. The microarray is a main technology realizing an analysis of miRNA expression spectrum and high-throughput detection of a variety of miRNAs at the same time. Its basic principle is based on the molecular hybridization technology. It can obtain expression spectrum of different miRNA specimens through detection on the intensity of hybridization signals, thus comparing the expression differences in miRNA specimens. Sorrentino *et al*.\[[@ref51]\] used microarray to analyze the mechanisms of let-7e, miR-30c, miR-125b, miR-130a and miR-335 in drug-resistant cells A2780TAX, A2780TC1, A2780TC3 (paclitaxel), and A2780CIS (resistance to cisplatin), and found that down-regulation of miRNA can activate chemotherapy-resistance gene M-CSF. This result showed that resistance to drug of ovarian cancer was associated with the miRNA expression spectrum. Through microarray has the advantage of high flux, it is susceptible to the interference of cross hybridization of homologous miRNA sequences, and the equipment are expensive. RT-PCR can observe the real-time signal changes during the experiment by fluorescence signal changes. It has high sensitivity and practicability. Currently, main fluorescent quantitative PCR methods include fluorochrome method and hydrolysis probe method. The commonly used fluorochrome is SYBR Green. For example, Lou *et al*.\[[@ref52]\] used SYBR Green I for fluorescence quantitative detection and found that low expression of miR-21 can obviously increase apoptosis of papillary ovarian cells OVCAR3 *in vitro* and reduce proliferation, invasion and migration ability of OVCAR3 cells. Suryawanshi *et al*.\[[@ref53]\] used SYBR Green ROX for fluorescence quantitative detection and found low expressions of miR-15 and miR-16 in ovarian cancer. Moreover, it results in the growth of tumor cells by combining with 3′UTR in Brni-1 gene, suggesting tumor suppressor role of miR-15 and miR-16. The advantage of SYBR Green is easy to use. It does not need to design complex fluorescent, so it simplifies the detection methods and reduces the cost. However, it has a certain inhibition on PCR. Moreover, the fluorescence intensity is low and instable. TaqMan probe is the representative of hydrolysis probes. Cittelly *et al*.\[[@ref54]\] confirmed ovarian cancer patients with low expression of targets (TUBB3) of antimicrotubular drugs had obviously longer survival period than patients with high expression of TUBB3 by TaqMan probe, suggesting miR-200c can increase the sensitivity of ovarian cancer tissues to chemotherapy drug taxol via target regulation on TUBB3. The emergence of TaqMan probe solves the non-specificity of fluorescent. At the reaction end, melting curve analysis is not needed, so the experimental time is shortened. But its price is high, and it is only suitable for a specific target and inconvenience to popularize and application. In addition, fluorescence group and quenching group on both sides of TaqMan probe are close to each other, so incomplete quenching results in high background. Since mature miRNA molecules only have 22 bases and the sequence is short, amplification reaction cannot be directly implemented by PCR. [Figure 2](#F2){ref-type="fig"} shows the schematic of these methods for expression profiling of miRNAs.\[[@ref55]\]

![Schematic description of the methods for expression profiling of microRNAs. (a) Northern blotting method; (b) Microarray method; (c) Two reverse transcription-polymerase chain reaction methods: (1) The SYBR Green reverse transcription-polymerase chain reaction method; (2) The TaqMan probe reverse transcription-polymerase chain reaction method.](CMJ-128-3363-g002){#F2}

With the development of nano science and technology, researchers have developed more and more new methods used in detection on sensitivity and specificity of miRNAs. These methods can be divided into two categories, one detection method is based on the sample amplification reaction; another detection method is based on the probe hybridization (sample without amplification).

Sample amplification detection methods mainly include rolling circle amplification (RCA), hybridization chain reaction (HCR) and ligase chain reaction (LCR), etc. RCA is an isothermal amplification technique copying circular template based on displacement activity of DNA polymerase chain. Cheng *et al*.\[[@ref56]\] induced RCA with miRNA as a primer. Moreover, the amplified product further induced branch rolling amplification as a primer, thus realizing detection on sensitivity and specificity of miRNA. Chapin and Doyle\[[@ref57]\] established a new RCA method on this basis. They used a probe that was fixed in hydrogel particles to capture miRNA and can quantitatively detect a variety of miRNAs. This method is of high sensitivity and good specificity. It can distinguish the mismatching of a base and the linear range crosses 6 magnitudes (300 aM-40 pM). HCR triggers long chain of nucleic acids with a gap by trigger chain, and achieve amplification detection on the target by competitive hybridization between nucleic acids. Yang *et al*.\[[@ref58]\] established a new method to detect miRNA based on the differences between grapheme oxide and single and double chains in acting forces and amplification of HCR signals. Ge *et al*.\[[@ref59]\] designed a probe based on the tetrahedron nanostructures of DNA. The new probe and HCR amplification method can largely increase the sensitivity of detection on miRNA. And the detection limit can reach 0.1 fM. LCR uses DNA ligase to build covalent phosphate bond, which connects double-stranded DNA specifically. After heating denaturation, annealing, and connection, cycles is repeated for many times, thus target DNA is amplified to a large amount. Yuan *et al*.\[[@ref60]\] established a new method detecting miRNA that was of high sensitivity by connecting LCR and fluorescence resonance energy transfer of cationic conjugated polymer assisted by lambda exonuclease. The new method can achieve high sensitivity detection on target miRNA (0.1 fM).

Probe hybridization is a direct detection method, we do not need to be preamplified RNA samples. These methods mainly include nano-gold labeling technique and direct quantitative analysis of multiple miRNAs (DQAMmiR). The basic principle of nano-gold labeling technique is based on the molecular hybridization technology. Alkyl thiol modified oligonucleotides can be combined with nano-gold covalent, and then the probe may be formed with the target miRNA sequence hybridization. Degliangeli *et al*.\[[@ref61]\] designed a probe based on the DNA-gold nanoparticle, which is immobilized on PEGylated gold nanoparticles (AuNPs). The DNA − AuNP probes can achieve high sensitivity detection on miR-203, and the detection limit can reach 0.2 fM. This new method can significantly advance the use of miRNAs as biomarkers in the clinical praxis. DQAMmiR is the new method to measure accurately amounts of multiple miRNAs in biological samples.\[[@ref62]\] MiRNAs and excessive DNA probe hybridization, and separation by capillary electrophoresis. Due to different miRNAs corresponding modified amino acid DNA probe length is different, so the migration velocity also different. Using this method can simultaneously detect more than 10 kinds of miRNAs.

With the rapid development of the miRNAs detection technology, this is widely used in many aspects of cancer early detection. However, it is worth pointing out that PubMed search with "miRNAs and cancer" lists around 16,717 publications, whereas search with the term "miRNAs and ovarian cancer" lists around 616 publications. Obviously, miRNAs have great prospects in the early detection of ovarian cancer.

C[ONCLUSIONS AND]{.smallcaps} P[ERSPECTIVES]{.smallcaps} {#sec1-6}
========================================================

Ovarian cancer has characteristics of high malignant degree, poor prognosis, and high mortality rate. In clinical, image detection is often used to find early the disease. Since miRNA is closely related to the occurrence and development of ovarian cancer, its expression is stable, and can be used as a marker for early diagnosis of ovarian cancer. Emerging evidence strongly supports the miRNAs have the potential to be useful diagnostic and prognostic biomarkers. Thus, in the near future, miRNA therapy could be a powerful tool for ovarian cancer prevention and treatment. It is worth noting that with the in-depth research of miRNAs, it is found the expression of miRNA is different in serum and plasma, and in patients' body fluid including ascites, pleural effusion, urine and saliva, etc. It can be imagined that this simple, convenient and less painful test method has profound significance for diagnosis, treatment, and prognosis for patients with ovarian cancer.

On the other hand, as miRNA plays more and more important role in early diagnosis of ovarian cancer. Although miRNA detection technologies are quickly developed, these new miRNA detections have not yet been used widely in early diagnosis of ovarian cancer. Therefore, by combining the new analysis technology and new nano materials, point-of-care tests for miRNA with high throughput, high sensitivity, and strong specificity are developed to achieve the application of diagnostic kits in the screening of early ovarian cancer.
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